CompletedNCT02577250
Ketamine Infusions for PTSD and Treatment-Resistant Depression
About this title
Read the official source — NCT02577250Medication studyAges 18–75United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
What did participation involve?
The study group receives ketamine as a study medication.
- Listed locations
- MinneapolisSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateMay 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Minneapolis Veterans Affairs Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT02577250
- Official title
Show the full official title
Efficacy and Safety of Repeated Intravenous Subanesthetic Ketamine Infusions Among Veterans With Treatment Resistant Depression Comorbid With Chronic Post-Traumatic Stress Disorder: A Proof-of-concept Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Minneapolis
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Minneapolis Veterans Affairs Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including ketamine.
Who was this study for?
Listed age limits: 18 years to 75 years.
